186 related articles for article (PubMed ID: 37274644)
1. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy.
Antonini G; Habetswallner F; Inghilleri M; Mantegazza R; Rodolico C; Saccà F; Sgarzi M; deRuyck F; Paci S; Phillips G; Crippa L; Veronesi C; Perrone V; Degli Esposti L;
Heliyon; 2023 Jun; 9(6):e16367. PubMed ID: 37274644
[TBL] [Abstract][Full Text] [Related]
2. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment.
Ting A; Story T; Lecomte C; Estrin A; Syed S; Lee E
J Neurol Sci; 2023 Feb; 445():120531. PubMed ID: 36634582
[TBL] [Abstract][Full Text] [Related]
3. Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey.
Mahic M; Bozorg A; DeCourcy J; Golden K; Gibson G; Taylor C; Scowcroft A
Orphanet J Rare Dis; 2023 Jun; 18(1):169. PubMed ID: 37386469
[TBL] [Abstract][Full Text] [Related]
4. Potentially inappropriate drug use in myasthenia gravis: a real-world population-based cohort study in Italy.
Crescioli G; Finocchietti M; Paoletti O; Brunori P; Sciancalepore F; Tuccori M; Addis A; Vannacci A; Lombardi N; Kirchmayer U;
Front Neurol; 2023; 14():1293626. PubMed ID: 38178892
[TBL] [Abstract][Full Text] [Related]
5. A national epidemiological study of Myasthenia Gravis in Australia.
Gattellari M; Goumas C; Worthington JM
Eur J Neurol; 2012 Nov; 19(11):1413-20. PubMed ID: 22469211
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of myasthenia gravis in Ontario, Canada.
Breiner A; Widdifield J; Katzberg HD; Barnett C; Bril V; Tu K
Neuromuscul Disord; 2016 Jan; 26(1):41-6. PubMed ID: 26573434
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.
Huang Q; Li F; Zhao S
BMC Neurol; 2022 Mar; 22(1):73. PubMed ID: 35246057
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
[TBL] [Abstract][Full Text] [Related]
9. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study.
Andersen JB; Owe JF; Engeland A; Gilhus NE
Eur J Neurol; 2014 Jul; 21(7):948-55. PubMed ID: 24712740
[TBL] [Abstract][Full Text] [Related]
10. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study.
Chen J; Tian DC; Zhang C; Li Z; Zhai Y; Xiu Y; Gu H; Li H; Wang Y; Shi FD
Lancet Reg Health West Pac; 2020 Dec; 5():100063. PubMed ID: 34327399
[TBL] [Abstract][Full Text] [Related]
11. The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan.
Herr KJ; Shen SP; Liu Y; Yang CC; Tang CH
Front Neurol; 2023; 14():1203679. PubMed ID: 37426446
[TBL] [Abstract][Full Text] [Related]
12. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
13. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Augusto MejíA-Vélez C
Muscle Nerve; 2017 Dec; 56(6):1041-1046. PubMed ID: 28214292
[TBL] [Abstract][Full Text] [Related]
14. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
Breccia M; Chiodi F; Nardozza AP; Valsecchi D; Perrone V; Sangiorgi D; Giacomini E; Rendace MC; Coco P; Premoli E; Degli Esposti L
Adv Ther; 2023 Mar; 40(3):961-974. PubMed ID: 36562943
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcome predictors of a Chinese childhood-onset myasthenia gravis cohort.
Yang L; Tang Y; He F; Zhang C; Kessi M; Peng J; Yin F
Front Pediatr; 2022; 10():996213. PubMed ID: 36245736
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases.
Santos E; Coutinho E; Moreira I; Silva AM; Lopes D; Costa H; Silveira F; Nadais G; Morais H; Martins J; Branco MC; Veiga A; Silva RS; Ferreira A; Sousa F; Freijo M; Matos I; André R; Negrão L; Fraga C; Santos M; Sampaio M; Lopes C; Leite MI; Gonçalves G
Muscle Nerve; 2016 Sep; 54(3):413-21. PubMed ID: 26851892
[TBL] [Abstract][Full Text] [Related]
17. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Cover Test Prior and Post Pyridostigmine in Diagnosis of Myasthenia Gravis.
Saint-Gerons M; Rubio MA; Martinez A; Matheu A
J Binocul Vis Ocul Motil; 2021; 71(2):71-76. PubMed ID: 33877951
[No Abstract] [Full Text] [Related]
19. Mortality and survival in myasthenia gravis: a Danish population based study.
Christensen PB; Jensen TS; Tsiropoulos I; Sørensen T; Kjaer M; Højer-Pedersen E; Rasmussen MJ; Lehfeldt E
J Neurol Neurosurg Psychiatry; 1998 Jan; 64(1):78-83. PubMed ID: 9436732
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
